Abstract:Gastrointestinal stromal tumours (GISTs) are soft-tissue sarcomas of the gastrointestinal tract. Surgery is the standard treatment for localised disease, but the risk of relapse and progression to more advanced disease is substantial. Following the discovery of the molecular mechanisms underlying GISTs, targeted therapies for advanced GIST were developed, with the first being the tyrosine kinase inhibitor (TKI) imatinib. Imatinib is recommended in international guidelines as first-line therapy to reduce the risk of GIST relapse in high-risk patients, and for locally advanced, inoperable and metastatic disease. Unfortunately, imatinib resistance frequently occurs and, therefore, second-line (sunitinib) and third-line (regorafenib) TKIs have been developed. Treatment options are limited for patients with GIST that has progressed despite these therapies. A number of other TKIs for advanced/metastatic GIST have been approved in some countries. Ripretinib is approved as fourth-line treatment of GIST and avapritinib is approved for GIST harbouring specific genetic mutations, while larotrectinib and entrectinib are approved for solid tumours (including GIST) with specific genetic mutations. In Japan, pimitespib, a heat shock protein 90 (HSP90) inhibitor, is now available as a fourth-line therapy for GIST. Clinical studies of pimitespib have indicated that it has good efficacy and tolerability, importantly not displaying the ocular toxicity of previously developed HSP90 inhibitors. Additional approaches for advanced GIST have been investigated, including alternative uses of currently available TKIs (such as combination therapy), novel TKIs, antibody-drug conjugates, and immunotherapies. Given the poor prognosis of advanced GIST, the development of new therapies remains an important goal.

Treatment Strategy for Recurrent and Metastatic Gastrointestinal Stromal Tumors

Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Followed by Sunitinib Compared to Followed by Imatinib-a Multi-Center Cohort Study

Treatment Strategies for Recurrent or Metastatic Gastrointestinal Stromal Tumor

Treatment of patients with postoperative recurrent-metastatic gastrointestinal stromal tumor

Resistance and Treatment Strategy of Gastrointestinal Stromal Tumor Target Therapy

[Strategies in Diagnosis and Management for Advanced or Metastatic Gastrointestinal Stromal Tumor].

[Significance of Surgical Treatment for Recurrent and Metastatic Gastrointestinal Stromal Tumors].

Status of surgical treatment in recurrent and metastatic gastrointestinal stromal tumors

Molecular targeted therapy for the treatment of gastrointestinal stromal tumor

[Treatment of Recurrent or Metastatic Gastrointestinal Stromal Tumor: Surgery or Not].

The strategy of surgical treatment and targeted therapy in gastrointestinal stromal tumors

Treatment of advanced gastrointestinal stromal tumors acquired resistance to imatinib

Management strategies for advanced gastrointestinal stromal tumors after failure of imatinib

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours

Role of surgery in treatment of recurrent or metastatic gastrointestinal stromal tumor

[Clinical Management of Advanced Gastrointestinal Stromal Tumors after Failure of at Least Both Imatinib and Sunitinib Targeted Therapy].

[Treatment Progress of Gastrointestinal Stromal Tumor].

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges

Progress in Diagnosis and Treatment of Gastrointestinal Stromal Tumors

[Challenges of Gastrointestinal Stromal Tumor in the Era of Targeted Therapy].

Strategy for better combination of targeted therapy and surgery in the treatment of gastrointestinal stromal tumor